AUPH FY2026 EPS Estimate Increased by Cantor Fitzgerald

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Cantor Fitzgerald lifted their FY2026 EPS estimates for Aurinia Pharmaceuticals in a research report issued on Wednesday, November 5th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will earn $0.99 per share for the year, up from their previous estimate of $0.74. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

AUPH has been the topic of several other reports. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Bloom Burton cut Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $10.00 to $21.00 in a research note on Friday. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $17.67.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock traded up $0.76 during trading on Friday, hitting $14.71. The stock had a trading volume of 1,258,739 shares, compared to its average volume of 1,653,120. The stock’s 50 day moving average is $12.22 and its two-hundred day moving average is $10.12. Aurinia Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $16.20. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of 34.33 and a beta of 1.30. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,744 shares during the last quarter. MAI Capital Management bought a new position in shares of Aurinia Pharmaceuticals in the first quarter worth approximately $39,000. DekaBank Deutsche Girozentrale purchased a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $60,000. Xponance Inc. bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $82,000. Finally, Kazazian Asset Management LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $84,000. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.